Cassava Sciences Inc. (NASDAQ: SAVA) stock declined by 17.04% during current market trading. Cassava Sciences’ goal is to find and develop new treatments for chronic neurological diseases. Cassava Sciences has spent the last ten years combining cutting-edge technology with cutting-edge neuroscience to produce innovative Alzheimer’s disease treatments.
What’s happening with SAVA stock?
Cassava Sciences reported today that an interim analysis of an open-label study using simufilam, SAVA’s experimental medication for the therapy of Alzheimer’s disease, revealed encouraging clinical findings.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Simufilam dramatically improved memory in Alzheimer’s patients in clinical research supported by the National Institutes of Health (NIH), with no side effects. Simufilam increased cognitive scores on the ADAS-Cog11 by 3.0 points, or 18%, from baseline to month 9 (p0.001). The clinical results from the first 50 patients with moderate to severe Alzheimer’s disease who finished 9 months of open-label simufilam therapy are summarized in this interim analysis.
Cassava Sciences claims that these findings are the first to show substantial cognitive improvements in Alzheimer’s patients after nine months, as well as significant increases in biomarkers.
Remi Barbier, President & CEO stated,
They are quite satisfied with the data’s general consistency. Simufilam enhanced cognition, biomarkers, and behavior, giving research participants a three-fold benefit. These clinical findings, along with a favorable safety profile and simple oral administration, point to extremely promising and long-lasting therapeutic results for Alzheimer’s patients.
Alzheimer’s is a disease that worsens with time. Cognition will inevitably deteriorate with age. According to the research literature, cognitive scores on the ADAS-Cog drop over 4 points in mild-to-moderate Alzheimer’s disease patients over 9 months with over 90% confidence.
At 9 months, Simufilam improved ADAS-Cog scores in 66% of patients. At 9 months, an additional 22% of patients deteriorated less than documented in the scientific literature. The results of the cognitive tests show that simufilam’s therapeutic effects were widespread. Anxiety, agitation, and delusions are common behavioral problems associated with Alzheimer’s disease. As the illness advances, they may become increasingly common.